ALFA Filings
Every announcement, straight from the exchange
Every Emcure Pharmaceuticals other announcement announcement on NSE and BSE, newest first, each with its own page.
Time
6 announcements with these filters
Emcure Pharmaceuticals submitted its quarterly shareholding pattern for the period ended September 30, 2026. This filing is a routine regulatory compliance disclosure under SEBI.
Emcure Pharmaceuticals has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 as part of its Annual Report.
Emcure Pharmaceuticals filed its quarterly shareholding pattern for the period ending June 30, 2026. The filing includes details of promoter and public shareholdings.
Emcure Pharmaceuticals Limited submitted its Annual Secretarial Compliance Report for FY2026. The report by Mehta & Mehta confirms full regulatory compliance with no adverse observations.
Emcure Pharmaceuticals was assigned an ESG rating of 21 by NSE Sustainability Ratings for FY 2024-25. This independent assessment reflects its environmental and social performance.
Emcure Pharmaceuticals Limited submitted its quarterly compliance certificate under SEBI Regulation 74(5) for the period ending March 31, 2026. The certificate from RTA MUFG Intime India confirms that security certificates received for dematerialisation were processed and cancelled within prescribed timelines.